Zoetis (NYSE:ZTS) Releases FY22 Earnings Guidance

Zoetis (NYSE:ZTSGet Rating) issued an update on its FY22 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $4.99-$5.09 for the period, compared to the consensus estimate of $5.16. The company issued revenue guidance of $8.225-$8.375 billion, compared to the consensus revenue estimate of $8.41 billion.

Shares of Zoetis stock opened at $171.45 on Friday. The firm has a market cap of $80.89 billion, a PE ratio of 40.15, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77. The firm’s 50-day simple moving average is $188.02 and its 200-day simple moving average is $205.37. The company has a debt-to-equity ratio of 1.45, a quick ratio of 2.79 and a current ratio of 3.86. Zoetis has a 1 year low of $165.22 and a 1 year high of $249.27.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. Zoetis had a net margin of 26.20% and a return on equity of 50.71%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the prior year, the firm earned $1.26 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, equities analysts predict that Zoetis will post 5.14 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 1st. Investors of record on Thursday, April 21st will be given a dividend of $0.325 per share. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Wednesday, April 20th. Zoetis’s dividend payout ratio is presently 30.45%.

Several research analysts have commented on the stock. StockNews.com cut shares of Zoetis from a strong-buy rating to a buy rating in a research report on Tuesday, April 26th. Citigroup decreased their price objective on shares of Zoetis from $232.00 to $208.00 and set a neutral rating for the company in a report on Wednesday, March 9th. Finally, Zacks Investment Research cut shares of Zoetis from a buy rating to a hold rating and set a $242.00 price objective for the company. in a report on Saturday, January 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $224.78.

In other news, EVP Roxanne Lagano sold 2,065 shares of the stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $196.54, for a total transaction of $405,855.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Glenn David sold 32,390 shares of the stock in a transaction on Wednesday, February 23rd. The stock was sold at an average price of $189.87, for a total transaction of $6,149,889.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,622 shares of company stock valued at $9,995,351. 0.12% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. Morgan Stanley boosted its holdings in Zoetis by 4.6% in the 2nd quarter. Morgan Stanley now owns 7,561,487 shares of the company’s stock valued at $1,409,158,000 after purchasing an additional 333,952 shares during the period. Barclays PLC boosted its holdings in Zoetis by 23.1% in the 4th quarter. Barclays PLC now owns 1,115,154 shares of the company’s stock valued at $272,130,000 after purchasing an additional 209,028 shares during the period. Comerica Bank boosted its holdings in Zoetis by 88.5% in the 3rd quarter. Comerica Bank now owns 414,953 shares of the company’s stock valued at $86,066,000 after purchasing an additional 194,874 shares during the period. NewEdge Advisors LLC boosted its holdings in Zoetis by 100.5% in the 4th quarter. NewEdge Advisors LLC now owns 16,769 shares of the company’s stock valued at $4,093,000 after purchasing an additional 8,407 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Zoetis by 31.0% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 34,345 shares of the company’s stock valued at $8,381,000 after purchasing an additional 8,118 shares during the period. Institutional investors and hedge funds own 90.73% of the company’s stock.

Zoetis Company Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.